Apollomics, Inc. Company Operational Continuity Update

Rhea-AI Summary

Apollomics (Nasdaq: APLM) announced operational continuity after a leadership change and new funding, reversing prior wind-up plans.

The company said it received $4.1 million in PIPE funding on Sept 3, 2025, appointed a new board and management team, and intends to continue its global Phase 2 SPARTA program for APL-101 (vebreltinib), which has data from >280 patients. All CRO contracts are reported fully paid; the company has 12 employees and expects 15 by Oct 31, 2025. Apollomics also cites existing Chinese approvals for APL-101 in MET-amplified NSCLC and GBM via partners and intends to pursue broader regulatory filings.

Positive

• $4.1M PIPE funding received on Sept 3, 2025
• Reversal of wind-up; management committed to continue Phase 2 SPARTA
• All current CRO contracts reported fully paid
• Chinese approvals for APL-101 in MET-amplified NSCLC and GBM via partners

Negative

• Prior Aug 28, 2025 announcement expected to discontinue APL-101 trials
• Small headcount: 12 employees may constrain operations
• Planned reduction of China headcount could disrupt China programs

Insights

Corporate Restructuring Analyst

Company reversed wind-up after a $4.1 million PIPE, restored leadership, and confirmed operational continuity.

Apollomics reopened operations after the prior board signaled an expected wind-up and then accepted $4.1 million in PIPE capital on September 3, 2025. The new board appointed a new management team and says contracts with CROs are paid and current, which reduces immediate counterparty and operational disruption risk.

Key dependencies and risks include the sufficiency of $4.1 million to fund near-term obligations, the company’s plan to grow headcount from 12 to 15 by October 31, 2025, and the stated intent to reallocate resources geographically. Watch quarterly cash burn, any additional financing or creditor obligations, and CRO confirmations of uninterrupted trial activity over the next 12 months.

Clinical Development Strategist

SPARTA Phase 2 for APL-101 continues with ongoing global sites and over 280 patients previously enrolled.

Apollomics states it will continue the multi-country, multi-center SPARTA program for APL-101 (vebreltinib), a late-stage program described as having positive results in trials involving over 280 patients. The company highlights approvals for APL-101 in China for MET-amplified NSCLC and GBM via its licensing partner and plans to leverage those for other markets.

Operational continuity reduces the immediate risk of trial stoppage, but the program depends on sustained funding, regulatory interactions in the U.S. and EU, and partner support in China and Taiwan. Monitor enrollment status, data-readiness milestones for SPARTA, and any regulatory filings or additional financing announcements over the next 12 months.

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.

Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics’ strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to overcome resistance and deliver meaningful clinical outcomes. The Company is currently conducting a global Phase 2 trial of APL-101 (vebreltinib), a promising targeted therapy that has seen positive results from clinical trials involving over 280 patients. With its late-stage clinical trial status and its history of positive patient developments, APL-101 represents a core investment of Apollomics that must be continued and further developed.

On August 28, 2025, the Company, citing financial concerns, announced on Form 6-K (the “August 28 Announcement”) that it “expected” to discontinue all clinical trial activities related to APL-101 (vebreltinib) (also known as SPARTA) and that it intended to seek shareholder approval to wind up the Company’s business.

On September 3, 2025 (the “September 3 Funding”), the Company announced on Form 6-K that it had received $4.1 million PIPE investments from certain investors and appointed a new board of directors (the “Current Board”). The Current Board subsequently appointed a new management team, led by Hung-wen (Howard) Chen (“Howard Chen”), as Chief Executive Officer, and Yi-kuei (Alex) Chen (“Alex Chen”), as Chief Operating Officer, and Peter Lin, as Chief Financial Officer.

With additional funding and new leadership, the Company has reversed its wind-up plans. Apollomics is continuing pre-existing operations and advancing the global development and commercialization of its intellectual property assets, such as APL-101 (vebreltinib). Although the former Board and management of Apollomics had announced that they “expect[ed]” to discontinue the SPARTA clinical trials associated with APL-101, there has been no stoppage, and under its current management, Apollomics aims to complete the clinical trials. Promptly after the September 3 Funding, the Company’s new management team began notifying its clinical research organizations (“CROs”) and licensing partners (including its CRO associated with the SPARTA trials of vebreltinib (Sofpromed Investigación Clínica, S.L.), its CRO and licensing partner in China (Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd), and its licensing partner in Taiwan (LaunXP Biomedical Co., Ltd.)) about the leadership transition and continuity of operations and clinical trials. All contracts with the Company’s current CROs are fully paid and up to date.

The Company has developed a comprehensive business plan for the next 12 months to ensure continued operations and strengthen its clinical development programs. Apollomics remains committed to the ongoing global multi-country, multi-center SPARTA clinical trial of APL-101 (vebreltinib). This program is important for maximizing the therapeutic potential of vebreltinib across multiple tumor types and to support regulatory submissions in the U.S., EU, and other major markets. In addition, the Company intends to leverage Chinese APL-101 (vebreltinib) approvals for MET-amplified NSCLC and GBM, obtained via its CRO and licensing partner in China, to pursue regulatory submissions in Southeast Asia, the Middle East, and other potential emerging markets outside of China.

Apollomics currently has 12 full time employees. Apollomics expects total headcount to reach 15 by October 31, 2025į. Apollomics believes that the current headcount is sufficient to maintain clinical trials and operations. Apollomics also intends to reduce headcount in China and re-allocate headcount to the U.S. and Taiwan.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States, China, member states of the European Union, Taiwan and other jurisdictions affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward- looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward- looking statements, except to the extent required by applicable law.

peter.lin@apollomicsinc.com

FAQ

What did Apollomics (APLM) announce on October 14, 2025 about its operations?

Apollomics said it reversed prior wind-up plans after new leadership and $4.1M PIPE funding and will continue global development of APL-101 (vebreltinib).

How much funding did Apollomics (APLM) receive on Sept 3, 2025 and why does it matter?

Apollomics received $4.1 million in PIPE investments on Sept 3, 2025, enabling management to continue clinical programs and reverse wind-up plans.

Will Apollomics (APLM) continue the global Phase 2 SPARTA trial for APL-101 (vebreltinib)?

Yes. The company states it intends to continue and complete the global multi-country Phase 2 SPARTA trial for APL-101.

What regulatory progress does Apollomics (APLM) cite for APL-101 (vebreltinib)?

The company references Chinese approvals for APL-101 in MET-amplified NSCLC and GBM obtained via its China partner and plans to leverage those approvals for other markets.

Are Apollomics' CRO contracts current and paid?

Yes. Apollomics reports that all contracts with its current CROs are fully paid and up to date.

How many employees does Apollomics (APLM) have and what are hiring plans by Oct 31, 2025?

Apollomics currently has 12 full-time employees and expects headcount to reach 15 by Oct 31, 2025.